Genentech has withdrawn the U.S. accelerated approval indication for Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1, as determined by an FDA)-approved test.
With NCI Director Anthony Letai in Milan supporting his daughter, Julie, at the 2026 Winter Olympics, Douglas R. Lowy, principal deputy director of NCI, took on the job of delivering detailed remarks and fielding questions at the inaugural meeting of the NCAB’s ad hoc working group on Extramural Research Concepts and Programs.
